SG10201800162RA - Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines - Google Patents

Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines

Info

Publication number
SG10201800162RA
SG10201800162RA SG10201800162RA SG10201800162RA SG10201800162RA SG 10201800162R A SG10201800162R A SG 10201800162RA SG 10201800162R A SG10201800162R A SG 10201800162RA SG 10201800162R A SG10201800162R A SG 10201800162RA SG 10201800162R A SG10201800162R A SG 10201800162RA
Authority
SG
Singapore
Prior art keywords
substituted
pyrazines
triazolo
dihydro
acyl
Prior art date
Application number
SG10201800162RA
Inventor
Hamid Hoveyda
Guillaume Dutheuil
Original Assignee
Ogeda Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogeda Sa filed Critical Ogeda Sa
Publication of SG10201800162RA publication Critical patent/SG10201800162RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
SG10201800162RA 2014-09-25 2015-09-25 Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines SG10201800162RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14186447 2014-09-25

Publications (1)

Publication Number Publication Date
SG10201800162RA true SG10201800162RA (en) 2018-02-27

Family

ID=51730305

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702368PA SG11201702368PA (en) 2014-09-25 2015-09-25 Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
SG10201800162RA SG10201800162RA (en) 2014-09-25 2015-09-25 Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201702368PA SG11201702368PA (en) 2014-09-25 2015-09-25 Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines

Country Status (18)

Country Link
US (2) US20170298070A1 (en)
EP (1) EP3197876B1 (en)
JP (1) JP6469214B2 (en)
KR (1) KR102558711B1 (en)
CN (1) CN107001289B (en)
AU (1) AU2015323702B2 (en)
CA (1) CA2961984C (en)
EA (1) EA032052B1 (en)
ES (1) ES2711095T3 (en)
IL (1) IL251304B (en)
MX (1) MX367633B (en)
NZ (1) NZ730295A (en)
PL (1) PL3197876T3 (en)
PT (1) PT3197876T (en)
SG (2) SG11201702368PA (en)
TR (1) TR201902080T4 (en)
WO (1) WO2016046398A1 (en)
ZA (1) ZA201701949B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54833B1 (en) 2011-10-03 2016-10-31 Euroscreen Sa Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JP6316932B2 (en) 2013-03-29 2018-04-25 オゲダ エス.エー. Novel N-acyl- (3-substituted)-(8-substituted) -5,6-dihydro- [1,2,4] triazolo [4,3-a] as selective NK-3 receptor antagonists Pyrazine, pharmaceutical composition, method of use in NK-3 receptor mediated disorder
SG11201707521QA (en) 2015-03-16 2017-10-30 Ogeda Sa Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
JP2021014404A (en) * 2017-10-13 2021-02-12 アステラス製薬株式会社 Triazolopyrazine derivative salt and crystal
WO2022031773A1 (en) 2020-08-04 2022-02-10 Teva Pharmaceuticals International Gmbh Solid state forms of fezolinetant and salts thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3252483B2 (en) 1992-10-20 2002-02-04 東レ株式会社 Method for producing tricyclic triazolo derivative
SK13532001A3 (en) 1999-04-01 2003-02-04 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE60316416T2 (en) 2002-03-25 2008-06-26 Merck & Co., Inc. HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE FOR TREATMENT OR PREVENTION OF DIABETES
ATE335744T1 (en) 2002-08-07 2006-09-15 Novartis Pharma Gmbh ORGANIC COMPOUNDS AS AGENTS FOR TREATING ALDOSTERONE-RELATED CONDITIONS
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AR043443A1 (en) 2003-03-07 2005-07-27 Merck & Co Inc PROCEDURE FOR THE PREPARATION OF TETRAHYDROTRIAZOLOPIRAZINS AND INTERMEDIATE PRODUCTS
DE602005008558D1 (en) 2004-02-18 2008-09-11 Astrazeneca Ab CONDENSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF METABOTROPIC REINFORCEMENTS
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
JP5635910B2 (en) 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド 5H-cyclopenta [d] pyrimidine as an AKT protein kinase inhibitor
WO2009090055A1 (en) 2008-01-17 2009-07-23 Grünenthal GmbH Substituted sulfonamide derivatives
JP5654001B2 (en) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドGlaxo Group Limited 5,6,7,8-tetrahydro [1,2,4] triazolo [4,3-a] pyrazine derivatives as P2X7 modulators
WO2011007756A1 (en) 2009-07-13 2011-01-20 武田薬品工業株式会社 Heterocyclic compound and use thereof
BR112012025101B1 (en) 2010-04-02 2021-08-31 Ogeda S.A. Selective nk-3 receptor antagonist compounds, pharmaceutical composition and drug comprising them
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
RS54833B1 (en) 2011-10-03 2016-10-31 Euroscreen Sa Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders
CA2907813C (en) 2013-03-29 2021-09-07 Euroscreen Sa Novel n-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
JP6316932B2 (en) 2013-03-29 2018-04-25 オゲダ エス.エー. Novel N-acyl- (3-substituted)-(8-substituted) -5,6-dihydro- [1,2,4] triazolo [4,3-a] as selective NK-3 receptor antagonists Pyrazine, pharmaceutical composition, method of use in NK-3 receptor mediated disorder
EP2989103B1 (en) 2013-03-29 2019-02-20 Ogeda Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders

Also Published As

Publication number Publication date
US10787458B2 (en) 2020-09-29
PT3197876T (en) 2019-02-21
MX2017003980A (en) 2017-05-08
US20190218225A1 (en) 2019-07-18
SG11201702368PA (en) 2017-04-27
CA2961984A1 (en) 2016-03-31
ES2711095T3 (en) 2019-04-30
BR112017005880A2 (en) 2018-02-06
ZA201701949B (en) 2021-06-30
TR201902080T4 (en) 2019-03-21
US20170298070A1 (en) 2017-10-19
CA2961984C (en) 2023-01-24
CN107001289A (en) 2017-08-01
MX367633B (en) 2019-08-29
WO2016046398A1 (en) 2016-03-31
EA032052B1 (en) 2019-03-29
JP6469214B2 (en) 2019-02-13
AU2015323702B2 (en) 2020-03-12
AU2015323702A1 (en) 2017-04-13
JP2017529370A (en) 2017-10-05
EP3197876B1 (en) 2018-11-28
IL251304A0 (en) 2017-05-29
EP3197876A1 (en) 2017-08-02
IL251304B (en) 2019-07-31
NZ730295A (en) 2023-05-26
PL3197876T3 (en) 2019-05-31
CN107001289B (en) 2019-12-31
KR102558711B1 (en) 2023-07-21
KR20170072898A (en) 2017-06-27
EA201790540A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
HK1245764A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
HK1244787A1 (en) Novel 5 or 8-substituted imidazo [1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases
IL251304A0 (en) Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines
IL254224A0 (en) 7-substituted-5-alkyl-[1,2,4] triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
HK1256751A1 (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
HUE043122T2 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
IL243092B (en) Novel triazolo[4,5-d]pyrimidine derivatives
IL266305B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
IL247947B (en) Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
IL272988A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK1254651A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide